DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil
Drug: Placebo
Drug: Olmesartan
Drug: Valsartan

First Posted Date: 2008-06-12

Last Posted Date: 2011-04-19

Lead Sponsor: Takeda

Target Recruit Count: 1291

Registration Number: NCT00696436

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil with or without add-on chlorthalidone
Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide

First Posted Date: 2008-06-12

Last Posted Date: 2011-04-19

Lead Sponsor: Takeda

Target Recruit Count: 669

Registration Number: NCT00695955

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2008-05-13

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT00676260

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: TAK-442
Drug: Placebo

First Posted Date: 2008-05-13

Last Posted Date: 2016-04-13

Lead Sponsor: Takeda

Target Recruit Count: 2753

Registration Number: NCT00677053

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Vortioxetine
Drug: Duloxetine

First Posted Date: 2008-05-06

Last Posted Date: 2013-12-18

Lead Sponsor: Takeda

Target Recruit Count: 611

Registration Number: NCT00672620

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2008-05-06

Last Posted Date: 2013-12-13

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT00672958

Efficacy of Ramelteon in Adults With Chronic Insomnia

Phase 3

Terminated

Conditions: Chronic Insomnia

Interventions: Drug: Ramelteon
Drug: Placebo

First Posted Date: 2008-05-06

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 1081

Registration Number: NCT00672724

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

Phase 4

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone

First Posted Date: 2008-05-06

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 305

Registration Number: NCT00672919

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease
COPD

Interventions: Drug: Ramelteon and Placebo

First Posted Date: 2008-05-06

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT00672802

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

Phase 2

Completed

Conditions: Sleep Apnea, Obstructive

Interventions: Drug: Ramelteon or Placebo

First Posted Date: 2008-05-06

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT00672061

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy